SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia shares are under pressure as traders react to the boards investigation into Jensen Huangs admitted affair with a businesswoman reported to have suspected ties to Chinese intelligence, raising concerns about governance, possible information leaks, and Huangs future as CEO. The community is divided between seeing the probe and leadership uncertainty as a serious overhang and treating the controversy as unrelated to Nvidias AI-chip business and a buying opportunity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is under heavy selling pressure ahead of its Q3 earnings report, with traders speculating about a possible leak while others see the decline as pre-report positioning; a leak is unconfirmed. Bulls point to growth and potential upbeat guidance, while bears worry that the Eli Lilly obesity-drug deal could pressure margins and profitability.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly revenue beat and higher full-year outlook, driven by BRIUMVI growth, are the main focus; shares saw a sharp post-results dip and recovery, prompting debate over a sell the news reaction versus short-driven volatility. Traders are also watching for Phase 3 results on subcutaneous BRIUMVI as a next potential catalyst.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWMs sharp rally is drawing attention as small caps outperform, with traders describing a possible low-volume short squeeze and rotation into the Russell 2000. Bulls are chasing calls and citing hopes for easing inflation, while skeptics question the moves strength given reported weak flows and limited volume.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy, focused on the amended upper-limb-function evidence from HOPE-3, is driving attention ahead of the Nov. 22 PDUFA date. Bulls cite the trial data and a letter urging approval from 28 investigators, while skeptics point to FDA scrutiny and the earlier negative advisory-panel vote on the cardiac indication; short-squeeze speculation adds to the debate.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs rally is drawing attention after Oppenheimer upgraded the stock, while Google Clouds use of EPYC processors in its AI infrastructure added a company-specific catalyst. Traders also point to money rotating from Nvidia amid a CEO-related investigation, though some see the move as sentiment-driven and question AMDs valuation.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels SITC findings on immune activation and viral clearance, alongside its positive Phase 3 prostate-cancer results, are drawing attention as the company prepares a BLA for CAN-2409. Bulls see the data as supportive of the regulatory package, while skeptics question filing and manufacturing execution and warn of a possible sell-the-news reaction.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

A quarterly earnings shortfall and reduced full-year revenue guidance, tied largely to federal Dedrone drone deployments being delayed, have driven a sharp selloff. Traders debate whether the decline overreacts to a timing issue or reflects high valuation and weaker near-term growth, with some buying the dip and others expecting further downside.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk shares are rallying sharply ahead of its Q3 earnings report, with traders speculating about short covering and an earnings leak, though neither explanation is confirmed. The move has fueled hopes for a turnaround, while many investors worry that weak results or guidance could erase the gains.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Agility Robotics Inc.

Agility Robotics Inc. - Ordinary Shares - Class A

Post-merger selling in Agility Robotics is drawing attention, with traders pointing to typical de-SPAC volatility and questioning the companys steep losses, limited revenue, and path to commercial scale. Some remain bullish on humanoid robotics and the companys reported orders, but the discussion is dominated by skepticism about valuation and near-term execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zoetis Takes Over #296 Spot From ResMed

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Zoetis Inc (Symbol: ZTS) has taken over the #296 spot from ResMed Inc. (Symbol: RMD), according to The Online Investor.

 Market capitalization is an important data poi...

ResMed Now #295 Largest Company, Surpassing Mettler-Toledo International

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, ResMed Inc. (Symbol: RMD) has taken over the #295 spot from Mettler-Toledo International, Inc. (Symbol: MTD), according to The Online Investor.

 Market capitalization...

ResMed: 3 Key Takeaways for Long-Term Investors

Key PointsResMed reported that core constant currency revenue grew 7% in the first quarter...

ResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs

ResMed's first-quarter fiscal 2027 earnings and revenues top estimates as sustained sleep device demand, productivity gains and gross margin expansion drive growth.

ResMed (RMD) Beats Q1 Earnings and Revenue Estimates

ResMed (RMD) delivered earnings and revenue surprises of +8.99% and +1.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Here's Why ResMed (RMD) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

If You Invested $1000 In ResMed Stock 20 Years Ago, You Would Have This Much Today

ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 3.82% on an annualized basis producing an average annual return of 12.81%. Currently, ResMed has a market capitalization of $36.18 billion.
Buyingread more...

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

• Reported GAAP EPS of $2.91 up 14.12% YoY
• Reported revenue of $1.41B up 5.93% YoY
• Resmed maintained FY 2027 guidance, unchanged from August 6, 2026: core constant currency revenue growth of 57%, reported revenue of $5.75B, and non-GAAP diluted EPS of $12.00$12.25.

Resmeds operating margins declined year over year, operating and free cash flow declined, and global Life Support Devices revenue fell 84% to $4M in Q1 FY2027.

Resmeds Q1 revenue and sleep and breathing health sales increased; Resmed launched AirTouch F40 in the U.S., partnered with Eight Sleep, and expanded non-GAAP gross margin while diluted EPS increased.

ResMed, Inc. engages in the design, manufacture, and marketing of equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, as well as the provision of software solutions for residential care providers. It operates through the following segments: Sleep and Breathing Health and Residential Care Software. The Sleep and Breathing Health segment relates primarily to the sale of therapy-based equipment. The Residential Care Software segment provides software access with ongoing support and maintenance services as well as professional services such as training and consulting. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Resmed Inc.

ResMed Draws Analyst Skepticism After Apnimed Announces Positive Results From Investigational Sleep Apnea Drug: Retail’s Unmoved

Equity

Bearish Sentiment

Analysts expect a negative impact on ResMed Inc. (RMD) after privately held pharmaceutical company and rival Apnimed, Inc. announced positive results from its late-stage clinical trial evaluating the efficacy of its lead candidate AD109 in treating obstructive sleep apnea.Apnimed <a target="_blank" rel="noopener noreferrer nofollow" href="https://apnimed.com/article/ad109phase3toplineresults/">said</a> on Tuesday that it plans to submit a new drug application to the U.S. Food and Drug Administration (FDA) by early 2026 for regulatory review of AD109, a once-daily pill taken at bedtime.ResMed makes medical devices for treating sleep disorders such as sleep apnea.RBC Capital said in a note to investors on Tuesday that the successful commercialization of AD109 would likely negatively impact ResMed's addressable market as AD109 "could offer a less invasive, more user-friendly and viable alternative" to ResMed’s machines.RBC also noted that the company now has “a number of competitive threats on the horizon," including the possible return of Philips Respironics into the U.S. sleep apnea market after a recall of certain CPAP, BiPAP, and ventilator devices in 2021 because of potential health risks.RBC Capital has a ‘Sector Perform’ rating on ResMed, as per TheFly.Morgan Stanley analyst David Bailey, meanwhile, believes AD109 appears to focus on patients who are unable or refuse to tolerate CPAP, and expects only a “moderate” potential earnings impact for ResMed from Apnimed based on current data.Bailey keeps an ‘Overweight’ rating on ResMed with a $286 price target.On Stocktwits, retail sentiment around ResMed stayed within the ‘Neutral’ territory while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:630/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_20_at_2_20_51_PM_png_d714f3fa97.webp" alt="RMD's Sentiment Meter and Message Volume as of 2:20 p.m. ET on May 20, 2025 | Source: Stocktwits" width="630" height="64"><figcaption>RMD's Sentiment Meter and Message Volume as of 2:20 p.m. ET on May 20, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/RMD">RMD stock </a>was down 2% on Tuesday at noon. However, it has risen by about 9% this year and by over 13% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/trump-fails-to-convince-gop-holdouts-on-tax-bill/ch033eORbon">Trump Reportedly Fails To Convince GOP Holdouts On Tax Bill</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ResMed company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

RBC Capital noted that ResMed now has “a number of competitive threats on the horizon." 

Vanguard S&P 500 ETF

Vanguard Total Stock Market ETF

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Feed

News

Sentiment

Earnings

Fundamentals

Info

RMD News